Texas Instruments Inc. on Tuesday won a $1.2 billion bid to build a pipeline to deliver drug-delivery drugs through its Sklearn research platform, in what is expected to be a major milestone in a bid to expand its pipeline of drug delivery.
The company’s bid is the latest indication of the pace of expansion in the pipeline, which has been in rapid decline since the death of its founder, Peter Skrebels.
It comes amid growing concerns about the safety of Skrebils drug-dispensing system, which is under scrutiny by the Food and Drug Administration.
On Monday, the Federal Energy Regulatory Commission said it was investigating the Skrebiles drug dispensing system, saying it could not guarantee the safety and reliability of its dispensing systems.
The agency said it would require the company to make improvements to its drug-injection technology.
In its bid, Texas Instruments said it expects to deliver the Sklearn drug-purchasing pipeline to more than 200 U.S. clinics in 2019.
It also said it plans to create an advisory board that will include representatives from the FDA, the Food & Drug Administration and the Department of Energy.
The company’s pipeline of pipeline-delivering drugs will likely be able to deliver its first product, which it said will target diabetes patients.
Texas Instruments has said it will work with other companies to develop a pipeline of drugs that could be used in humans, but that the company was not expected to complete any drug-testing before the program is up and running.